
Superspreading event in a pre-symptomatic population

COVID-19 Genomic Epidemiology Toolkit: Module 2.4

Glen R. Gallagher, PhD
Division Director, Molecular Diagnostics and Virology
Massachusetts Department of Public Health





cdc.gov/coronavirus

Toolkit map

Part 1: Introduction

- 1.1 What is genomic epidemiology?
- 1.2 The SARS-CoV-2 genome
- 1.3 How to read phylogenetic trees
- 1.4 Emerging variants of SARS-CoV-2

Part 2: Case Studies

- 2.1 SARS-CoV-2 sequencing in Arizona
- 2.2 Healthcare cluster transmission
- 2.3 Workplace-community transmission
- 2.4 Superspreading event

Part 3: Implementation

- 3.1 Getting started with Nextstrain
- 3.2 Getting started with MicrobeTrace
- 3.3 Linking epidemiologic data



Skilled nursing facility (SNF) in Boston, MA

- 142-bed skilled nursing facility in Massachusetts
 - Short-term care, long-term care, and memory units
- Mean resident age was 83 years (IQR: 61 98)
- Minority (28%) of residents were male
- Selected to establish a dedicated COVID-19 rehabilitation center
 - Universal SARS-CoV-2 screening conducted in April 2020 prior to relocation of all residents

Intensive infection-prevention measures at SNF

- Strict visitation policy
- Daily symptom and temperature checks for residents and staff
- Masking
 - Universal masking for staff
 - Mandatory masking for residents leaving their room
- Increased attention to hand hygiene
- Facility admissions heavily restricted

Universal testing revealed a superspreading event

- Universal SARS-CoV-2 screening among reportedly asymptomatic residents and staff
- Overall, 61% (118/194) of persons tested positive by PCR
 - **85%** (82/97) of residents
 - **37**% (36/97) of staff
- Two weeks after initial testing, 31% (30/97) died; of those, 80% (24) tested positive

Timeline of specimen collection for PCR

April 1

Residents

97 NP swabs

54% (52)
 SARS-CoV-2
 positive



April 5

Residents*

45 NP swabs

• 69% (31) SARS-CoV-2 positive

*negative on April 1

April 6

Residents

0 NP swabs

<u>Staff</u>

97 NP swabs

• 37% (36) SARS-CoV-2 positive


NP: Nasopharyngeal

WGS to investigate SARS-CoV-2 spread

• Of 118 total cases, 70% (83) had genomes sequenced

Sequencing revealed rapid spread


- 90% (75/83) genomes comprised a single cluster
- Very little genetic variation, even for single introduction



Sequencing revealed rapid spread


 Date of common ancestor for this cluster estimated to March 20

 Supports spread of SARS-CoV-2 among asymptomatic persons



Not all introductions lead to rapid transmission

- Additional, small clusters also detected
 - Indicate multiple introductions with varied outcome
- Superspreading dramatically influences transmission dynamics
- All 3 putative introductions occurred despite infection control practices at the facility



Summary

- Genetic diversity in the main cluster was strikingly low, even for recent transmission from a single introduction
- This event might reflect:
 - Low diversity within the index patient, or
 - Superspreading event where transmission to secondary cases occurred through unusually close or prolonged contact, or the initial case having a very high viral load at the time
- Led to very little onward transmission, with little large-scale effect because it occurred in a relatively isolated population.

Take-away

 Intensive infection-prevention measures are essential but may be insufficient

- Screening of reportedly asymptompatic persons can identify early transmission and prevent further spread
- Genomic sequencing of this superspreading event revealed extremely low genetic diversity

Limitations

Some staff and/or residents may have had unidentified symptoms


Acknowledgements

- Broad Institute
 - Jacob Lemieux

Learn more

- Other modules in Part 2: Case Studies
 - Healthcare cluster transmission Module 2.2
 - Investigating Workplace-Community Transmission in an Outbreak Module
 2.3
- COVID-19 Genomic Epidemiology Toolkit
 - Find further reading
 - Subscribe to receive updates on new modules as they are released go.usa.gov/xAbMw





For more information, contact CDC 1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.



FOR WEBSITE

Further Reading:

- Lemieux et al. 2020. Science. https://science.sciencemag.org/content/early/2020/12/09/science.abe3261
- Goldberg et al. 2020. CID. https://doi.org/10.1093/cid/ciaa991

Resources:

Nextstrain build: https://auspice.broadinstitute.org/sars-cov-2/boston/gisaid-0929?f SNF A EXPOSURE=YES